EPIRUS Biopharmaceuticals, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | $3.7M | $2.3M | $8.2M | $46.7M |
| Operating income | −$52.3M | −$39.3M | −$7.6M | −$13.0M | −$42.7M | −$7.1M |
| Net income | −$138.8M | −$41.8M | −$8.0M | −$13.5M | −$42.0M | −$35.0M |
| Total assets | $72.3M | $51.4M | $32.1M | $61.4M | $79.9M | $82.7M |
| Total liabilities | $35.9M | $19.0M | — | — | — | — |
| Equity | $36.4M | $32.4M | −$39.4M | $31.0M | $43.9M | $63.0M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 23.5M | 26.1M | 127.3M | 104.8M | 99,239 | 89.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2015- Operating margin
- —
- Net margin
- —
- Return on equity
- −381.5%
- Return on assets
- −192.0%
- Return on capital (ROCE)
- −134.2%
- Liabilities / assets
- 49.7%
- Debt / equity
- 0.99×
- Book value / share
- $1.55
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2015- Altman Z″ (distress)
- -9.88distress
- Accruals / assets
- −127.6%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 15, 2016
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ticktin RobertOfficer — General Counsel | Feb 27, 2016 | Option exercise | 949 | — |
| Shea Thomas A.Officer — Chief Financial Officer | Feb 27, 2016 | Option exercise | 1,044 | — |
| Munshi AmitOfficer — Chief Executive Officer | Feb 27, 2016 | Option exercise | 1,519 | — |
| Wyand MichaelOfficer — Chief Technical Officer | Feb 27, 2016 | Option exercise | 1,044 | — |
| Ticktin RobertOfficer — General Counsel | Dec 21, 2015 | Buy | 3,000 | $3.72 |
| Vincent AurentzOfficer — Chief Business Officer | Dec 17, 2015 | Buy | 2,200 | $3.43 |
| Munshi AmitOfficer — Chief Executive Officer | Dec 16, 2015 | Buy | 8,270 | $2.80 |
| Munshi AmitOfficer — Chief Executive Officer | Dec 15, 2015 | Buy | 8,069 | $2.87 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard noticeAug 1, 2016
- Entered a material agreement · Terminated a material agreement · Bankruptcy or receivership · Director / officer change · Other material eventJul 25, 2016
- Entered a material agreement · Terminated a material agreement · Delisting / listing-standard notice · Director / officer change · Other material eventJul 1, 2016
- Entered a material agreement · Other material eventJun 14, 2016
- Costs from exit or disposal · Director / officer change · Other material eventMay 9, 2016
- Results of operationsMar 15, 2016
- Entered a material agreementMar 1, 2016
- Other material eventFeb 9, 2016
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.